◆
Dual synergistic secretagogue combination: GHRH analog + selective GHRP ghrelin-receptor agonist.
Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Research Dose Reference
Available in 10 mg blend (5mg / 5mg)
CJC-1295 (No DAC) + Ipamorelin
Recovery
Research dose range
0 mcg150 mcg300 mcg450 mcg600 mcg
Standard research range
200 - 400 mcg
Standard scientific protocol range (100-200mcg each, 1-2x daily) for optimal pulsatile secretion.
Research focus
Synergistic GH pulse stimulation & tissue repair
Observed window
8-16 weeks
Administration
1-2x daily laboratory protocol (evening/fasted)
Primary pathway
GHRH-R & GHS-R1a (Ghrelin Receptor)
Dosing synthesized from endocrinology literature and clinical secretagogue trial paradigms. For laboratory research only.
PROTOCOL BENEFITS
Engineered Outcomes
Dual SecretagogueAmplified GH PulseSelective Signaling
◆
Produces amplified pulsatile GH secretion far greater than either compound administered alone.
◆
Avoids elevation of cortisol, prolactin, or appetite stimulation characteristic of older secretagogues.
SCIENCE
How It Works.
This protocol blends CJC-1295 (No DAC / Modified GRF 1-29) with Ipamorelin. CJC-1295 stimulates the GHRH receptor, initiating growth hormone synthesis in anterior pituitary somatotrophs, while Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a), triggering intracellular calcium influx and vesicle release.
Because they act through two distinct yet complementary biochemical cascades, the resulting growth hormone pulse is multiplicative rather than additive, while somatostatin feedback remains intact to prevent receptor desensitization.
WHAT TO EXPECT
Acute GH/IGF-1 elevation occurs within 30–60 minutes of administration. Functional tissue recovery, sleep architecture, and lean body mass outcomes are evaluated over 8–16 weeks.
PROTOCOL NOTE
Available as CJC-1295 (No DAC) 5mg + Ipamorelin 5mg (10mg total blend). Strictly for research use.
FAQ
Protocol Questions
What is the difference between CJC-1295 without DAC and the DAC version?+
DAC allows the compound to bind to serum albumin, extending its active half-life for days. This formulation uses Modified GRF 1–29 without DAC to stimulate natural pulsatile growth hormone surges rather than continuous sustained elevation.
What does the 1:1 ratio signify in this blend?+
The 1:1 ratio denotes equal mass proportion per vial (5 mg CJC-1295 without DAC + 5 mg Ipamorelin) for dual-pathway synergistic pituitary stimulation.